human ovarian cancer tissue array Search Results


90
Pantomics Inc human ovarian cancer tissue array
Human Ovarian Cancer Tissue Array, supplied by Pantomics Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human ovarian cancer tissue array/product/Pantomics Inc
Average 90 stars, based on 1 article reviews
human ovarian cancer tissue array - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
SuperBioChips ihc specimens from the cj2 human ovarian cancer tissue array
(A) Using Oncomine TCGA ovarian cancer genomics (562 ovarian carcinoma samples analyzed on an Affymetrix Human Genome U133 array; 12,624 measured genes), we compared different ST mRNAs, including α2,3-, α2,6-, and α2,8-linked ST, with survival time using a tercile approach. Patients with an upper one-third mRNA expression were defined as the high subgroup, while others with lower two-thirds mRNA expression were defined as the low subgroup. (B-C) <t>IHC</t> analysis of ST3GalI was performed on commercial human ovarian cancer tissue array samples (Super Bio <t>Chips,</t> <t>CJ2,</t> Korea). The intensity scores were as follows: 0, no staining; 1, weak; 2, moderate; 3, strong. Low ST3GalI included weak, moderate or no staining; high ST3GalI was defined as strong staining. Scale bars representing 20μm were added from an image taken at identical magnification and resolution. The percentage was determined in the early stage (FIGO stage I &II) or late stage (FIGO stage III&IV) disease groups. The Fisher's exact test was used to statistically analyze the percentage for the early and late stages. Kaplan-Meier survival curves were used to analyze OS in low- and high-ST3GalIgroups. (D-E) Transwell migration and matrigel invasion of ES2 human ovarian cancer cells with either ST3GalI knocked-down or over-expressed was assayed. Total numbers of cells in 7 random fields were counted. Data shown are the mean ± SD of 3 separate experiments (*: p < 0.05, **: p <0.01.). Data on the Y-axis represented relative value compared to control. Immunoblots were quantified using Image J software.
Ihc Specimens From The Cj2 Human Ovarian Cancer Tissue Array, supplied by SuperBioChips, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ihc specimens from the cj2 human ovarian cancer tissue array/product/SuperBioChips
Average 90 stars, based on 1 article reviews
ihc specimens from the cj2 human ovarian cancer tissue array - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
SuperBioChips human ovarian cancer tissue arrays
(A) Using Oncomine TCGA ovarian cancer genomics (562 ovarian carcinoma samples analyzed on an Affymetrix Human Genome U133 array; 12,624 measured genes), we compared different ST mRNAs, including α2,3-, α2,6-, and α2,8-linked ST, with survival time using a tercile approach. Patients with an upper one-third mRNA expression were defined as the high subgroup, while others with lower two-thirds mRNA expression were defined as the low subgroup. (B-C) <t>IHC</t> analysis of ST3GalI was performed on commercial human ovarian cancer tissue array samples (Super Bio <t>Chips,</t> <t>CJ2,</t> Korea). The intensity scores were as follows: 0, no staining; 1, weak; 2, moderate; 3, strong. Low ST3GalI included weak, moderate or no staining; high ST3GalI was defined as strong staining. Scale bars representing 20μm were added from an image taken at identical magnification and resolution. The percentage was determined in the early stage (FIGO stage I &II) or late stage (FIGO stage III&IV) disease groups. The Fisher's exact test was used to statistically analyze the percentage for the early and late stages. Kaplan-Meier survival curves were used to analyze OS in low- and high-ST3GalIgroups. (D-E) Transwell migration and matrigel invasion of ES2 human ovarian cancer cells with either ST3GalI knocked-down or over-expressed was assayed. Total numbers of cells in 7 random fields were counted. Data shown are the mean ± SD of 3 separate experiments (*: p < 0.05, **: p <0.01.). Data on the Y-axis represented relative value compared to control. Immunoblots were quantified using Image J software.
Human Ovarian Cancer Tissue Arrays, supplied by SuperBioChips, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human ovarian cancer tissue arrays/product/SuperBioChips
Average 90 stars, based on 1 article reviews
human ovarian cancer tissue arrays - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

Image Search Results


(A) Using Oncomine TCGA ovarian cancer genomics (562 ovarian carcinoma samples analyzed on an Affymetrix Human Genome U133 array; 12,624 measured genes), we compared different ST mRNAs, including α2,3-, α2,6-, and α2,8-linked ST, with survival time using a tercile approach. Patients with an upper one-third mRNA expression were defined as the high subgroup, while others with lower two-thirds mRNA expression were defined as the low subgroup. (B-C) IHC analysis of ST3GalI was performed on commercial human ovarian cancer tissue array samples (Super Bio Chips, CJ2, Korea). The intensity scores were as follows: 0, no staining; 1, weak; 2, moderate; 3, strong. Low ST3GalI included weak, moderate or no staining; high ST3GalI was defined as strong staining. Scale bars representing 20μm were added from an image taken at identical magnification and resolution. The percentage was determined in the early stage (FIGO stage I &II) or late stage (FIGO stage III&IV) disease groups. The Fisher's exact test was used to statistically analyze the percentage for the early and late stages. Kaplan-Meier survival curves were used to analyze OS in low- and high-ST3GalIgroups. (D-E) Transwell migration and matrigel invasion of ES2 human ovarian cancer cells with either ST3GalI knocked-down or over-expressed was assayed. Total numbers of cells in 7 random fields were counted. Data shown are the mean ± SD of 3 separate experiments (*: p < 0.05, **: p <0.01.). Data on the Y-axis represented relative value compared to control. Immunoblots were quantified using Image J software.

Journal: Oncotarget

Article Title: α2,3-sialyltransferase type I regulates migration and peritoneal dissemination of ovarian cancer cells

doi: 10.18632/oncotarget.15994

Figure Lengend Snippet: (A) Using Oncomine TCGA ovarian cancer genomics (562 ovarian carcinoma samples analyzed on an Affymetrix Human Genome U133 array; 12,624 measured genes), we compared different ST mRNAs, including α2,3-, α2,6-, and α2,8-linked ST, with survival time using a tercile approach. Patients with an upper one-third mRNA expression were defined as the high subgroup, while others with lower two-thirds mRNA expression were defined as the low subgroup. (B-C) IHC analysis of ST3GalI was performed on commercial human ovarian cancer tissue array samples (Super Bio Chips, CJ2, Korea). The intensity scores were as follows: 0, no staining; 1, weak; 2, moderate; 3, strong. Low ST3GalI included weak, moderate or no staining; high ST3GalI was defined as strong staining. Scale bars representing 20μm were added from an image taken at identical magnification and resolution. The percentage was determined in the early stage (FIGO stage I &II) or late stage (FIGO stage III&IV) disease groups. The Fisher's exact test was used to statistically analyze the percentage for the early and late stages. Kaplan-Meier survival curves were used to analyze OS in low- and high-ST3GalIgroups. (D-E) Transwell migration and matrigel invasion of ES2 human ovarian cancer cells with either ST3GalI knocked-down or over-expressed was assayed. Total numbers of cells in 7 random fields were counted. Data shown are the mean ± SD of 3 separate experiments (*: p < 0.05, **: p <0.01.). Data on the Y-axis represented relative value compared to control. Immunoblots were quantified using Image J software.

Article Snippet: IHC specimens (59) from the CJ2 human ovarian cancer tissue array were obtained from a commercial tissue array (Super Bio Chips, Seoul, S. Korea) with complete clinical data, including clinical stage, grade and overall survival (OS).

Techniques: Expressing, Staining, Migration, Control, Western Blot, Software